申请人:GENFIT
公开号:US10799510B2
公开(公告)日:2020-10-13
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
本发明提供了新型 6-取代的[1,2,4]三唑并[4,3-b]哒嗪,它们是 Rev-Erb 的激动剂。这些化合物以及包含这些化合物的药物组合物适用于治疗任何激活 Rev-Erb 具有治疗效果的疾病,例如炎症和昼夜节律相关疾病或心脏代谢疾病。